Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel and Irinotecan in Advanced Gastric Cancer
NCT01136031Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jan 2008
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and irinotecan in gastric cancer (GC), sponsored by Seoul National University Hospital. Primary endpoints: Dose-limiting toxicity at 3 weeks and Response Rate. Started Jan 2008; status: completed.
02
Drugs
paclitaxelirinotecan
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01136031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01136031.